BHCM
IMRX icon

Brevan Howard Capital Management’s Immuneering IMRX Stock Holding History

Brevan Howard Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-86,236
Closed -$454K – 2303
2026
Q1 		$454K Buy
+86,236
New +$442K ﹤0.01% 1358

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Brevan Howard Capital Management's IMRX Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 86,236 shares — an estimated $454K sold.

Brevan Howard Capital Management first reported a position in IMRX in Q1 2026 and held it in 1 quarter. The position peaked at $454K in Q1 2026. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 86,236 Immuneering shares in Q2 2026, an estimated $454K.
  • Brevan Howard Capital Management first reported a position in Immuneering in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Immuneering position peaked at $454K in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.